Cancer Therapy: Preclinical

Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy

Darya Alizadeh, Leying Zhang, Christine E. Brown, Omar Farrukh, Michael C. Jensen, and Behnam Badie

Abstract

**Purpose:** Stimulation of toll-like receptor-9 by CpG oligodeoxynucleotides (CpG-ODN) has been shown to counteract the immunosuppressive microenvironment and to inhibit tumor growth in glioma models. These studies, however, have used high doses of CpG-ODN, which can induce toxicity in a clinical setting. The goal of this study was to evaluate the antitumor efficacy of multiple low-dose intratumoral CpG-ODN in a glioma model.

**Experimental Design:** Mice bearing 4-day-old intracranial GL261 gliomas received a single or multiple (two or four) intratumoral injections of CpG-ODN (3 μg) every 4 days. Tumor growth was measured by bioluminescent imaging, brain histology, and animal survival. Flow cytometry and cytotoxicity assays were used to assess anti-glioma immune response.

**Results:** Two and four intracranial injections of low-dose CpG-ODN, but not a single injection, eradicated gliomas in 70% of mice. Moreover, surviving animals exhibited durable tumor-free remission (> 3 months) and were protected from intracranial rechallenge with GL261 gliomas, showing the capacity for long-term antitumor immunity. Although most inflammatory cells seemed to increase, activated natural killer (NK) cells (i.e., NK+CD107a+) were more frequent than CD8+CD107a+ in the brains of rechallenged CpG-ODN–treated animals and showed a stronger *in vitro* cytotoxicity against GL261 target cells. Leukocyte depletion studies confirmed that NK cells played an important role in the initial CpG-ODN antitumor response, but both CD8 and NK cells were equally important in long-term immunity against gliomas.

**Conclusions:** These findings suggest that multiple low-dose intratumoral injections of CpG-ODN can eradicate intracranial gliomas possibly through mechanisms involving NK-mediated effector function.

Clin Cancer Res; 16(13); 3399–408. ©2010 AACR.

Despite aggressive treatment, the prognosis of patients with malignant gliomas, the most common type of primary brain neoplasm, remains dismal (1). In addition to the development of targeted therapies, immunotherapy is being studied as an adjunct treatment option for these tumors. The selectivity of immunotherapy and the long-lasting memory of the immune system suggest that immunotherapy can potentially prevent tumor recurrence that most often occurs within the site of therapy. Several early-stage clinical trials using vaccination approach have been conducted with modest clinical efficacy in selected patients (2–5). Although further research in this area is ongoing, the ability of gliomas to escape immune response will continue to be a significant obstacle to this strategy, as gliomas have developed several mechanisms to avoid the multiple effector arms of the immune system (6).

One strategy to overcome the local immunosuppressive tumor microenvironment is through the activation of the innate immune system (7–9). Toll-like receptor (TLR) family members are pattern recognition receptors that collectively recognize lipid, carbohydrate, peptide, and nucleic acid structures that are broadly expressed by microorganisms. Among their key functions, TLRs enhance the uptake of microorganisms by phagocytic cells and mediate leukocyte recruitment to infected tissues. This broad immune activation has made TLR agonists attractive candidates for vaccine adjuvants for cancer therapy. TLR9 is also found in brain microglia and macrophages (10), and direct injection of high doses of CpG oligonucleotides (CpG-ODN; 10-100 μg), a TLR9 ligand, into intracranial tumors triggers long-term immunity and tumor rejection in glioma- and neuroblastoma-bearing mice (11). CpG-ODN as a single intratumoral injection has also been studied in patients with recurrent gliomas, with tolerable toxicity and a partial tumor response in a few patients.
Translational Relevance

The prognosis of patients with malignant gliomas, the most common type of primary brain neoplasm, remains dismal even after aggressive multimodality treatment. Although immunotherapy is being investigated as an adjunct treatment, the ability of gliomas to escape immune response will continue to be a significant obstacle to this strategy. One approach to overcome the local immunosuppressive tumor microenvironment is the activation of the innate immune system by toll-like receptor agonists such as CpG oligonucleotides (CpG-ODN). Direct intratumoral injections of CpG-ODN at high doses can eradicate intracranial gliomas in animals and is currently being investigated in clinical trials. Because high-dose CpG-ODN can induce a significant inflammatory response in the brain, we evaluated the efficacy of low-dose injections in a murine glioma model. Here we report that multiple intracranial injections of CpG-ODN were nontoxic, effectively eradicated established gliomas, and triggered long-term immunity through activation of natural killer and CD8 cells. These findings have direct application to the design of future anti-glioma clinical trials with CpG-ODN.

(7, 12). Although higher CpG-ODN doses may improve clinical efficacy, significant inflammatory response in an already edematous brain may hinder this approach. Because repeated administration of CpG-ODN has resulted in sustained immune activation (13–15), we hypothesized that multiple low-dose CpG-ODN injections can also be used as an alternative to high-dose treatment strategy for gliomas.

Here we report that multiple injections of low-dose CpG-ODN induced long-term tumor remission in mice bearing established gliomas. The observed immunemediated tumor eradication correlated with increased activated natural killer (NK) cell activity and protected animals from tumor rechallenge. Our data indicate that multiple low-dose intratumoral injections of CpG-ODN eradicated intracranial gliomas through activation of NK cells and induced antitumor immunity through induction of both NK and CD8 cells.

Materials and Methods

Cell lines and cell cultures

GL261, a murine glioma cell line of C57BL/6 origin, was stably transfected with firefly luciferase expression vector, and positive clones (GL261-ffluc) were selected using zeocin (1 mg/mL) and G418. B16-F10, a melanoma cell line of C57BL/6 origin, was a gift from Dr. K. Aboody at City of Hope (Duarte, CA). All cell lines were cultured in DMEM supplemented with 10% fetal bovine serum, penicillin (100 units/mL), and streptomycin (100 μg/mL) at 37°C in a humidified 5% CO2 atmosphere.

Oligodeoxynucleotides

Single-stranded oligodeoxynucleotides CpG-ODN (5′-TGACGTGAACCTCGATGTA-3′) and control ODN (5′-TGACGTGAACCTCGATGTA-3′) were purchased from Integrated DNA Technologies (IDT). CpG-ODN and control ODN were reconstituted in sterile water at a concentration of 1 μg/μL and stored at −80°C for future use.

Tumor implantation, tumor treatments, and tumor rechallenge

All animals were housed and handled in accordance to the guidelines of City of Hope Institutional Animal Care and Use Committee. Intracranial tumor implantation was done as described previously (16). GL261-ffluc cells were harvested by trypsinization, counted, and re-suspended in PBS. C57BL/6 mice (The Jackson Laboratory) weighing 15 to 25 g were anesthetized by i.p. administration of ketamine (132 mg/kg) and xylazine (8.8 mg/kg) and immobilized in a stereotactic head frame. Through a small burr hole, 3 μL of PBS containing 1 × 10⁵ tumor cells were injected unilaterally at the coronal suture, 1 mm lateral to the midline, and 3 mm deep into the frontal lobes, using a Hamilton syringe (Fisher Scientific).

Four days after intracranial implantation of GL261-ffluc cells, mice received one or multiple (two or four) intracranial injections of CpG-ODN (3 μg), control ODN (3 μg), and PBS every 4 days. The intracranial treatment was administered through the initial burr hole aiming to target the tumor site (5-7 mice per group).

Three months after initial treatment with CpG-ODN, all surviving animals were imaged to confirm the tumor eradication and then rechallenged with either GL261 or B16-F10 (1 × 10⁵ cells; 6 mice per group). In some experiments, absence of tumor was also confirmed by tissue histology (2-3 mice per experiment).

Flow cytometry analysis

Tumors, brain tissues at the injection sites, spleen, and blood samples were harvested for flow cytometry. Samples were prepared for flow cytometry as described previously (17). Cell suspensions from brain tissue and spleen were forced through a 40-μm filter. Spleen and blood samples were incubated in Gey's buffer (pH 7.2) for 10 minutes. For extracellular staining of immune markers, freshly prepared samples were resuspended in 0.1 mol/L PBS containing 1% fetal bovine serum and 2 mmol/L EDTA and incubated with FcγIII/IIIR-specific antibody to prevent nonspecific binding. Samples were then stained with different combinations of antibodies (CD11b, CD45, Gr-1, CD8, NK1.1, CD1107a, CD4, and CD25) or isotype controls for 1 hour at 4°C. For intracellular staining, cells were fixed in 2% paraformaldehyde (Cell Sciences) and permeabilized in methanol before incubation with FoxP3 or IFNγ. All antibodies and isotype controls were
purchased from BD Biosciences or eBioscience, Inc. Fluorescence data were collected on a CyAn fluorescence cell sorter (BDIS). Inflammatory cells were gated and separated from the rest of sorted cells based on forward-scatter versus side-scatter analysis and their staining characteristics. FlowJo 8.4.7 software (Tree Star, Inc.) was used for data analysis and the proportion of each cell type was measured as percent of total inflammatory cells (4 mice per group).

Luciferase-based cytotoxicity assay

Blood samples were collected from cardiac puncture. Peripheral blood was diluted 1:3 in culture medium and layered on an equal volume of Ficoll Paque PLUS (GE Healthcare). The tubes were spun down for 20 minutes at 400 × g at room temperature. The peripheral blood mononuclear cells in the interphase were collected and washed twice in 12 mL of culture medium at 200 × g for 5 minutes. Brains were harvested, minced, and forced through a 40-μm cell strainer. Both brain and blood samples were stained with NK1.1, CD8, and PI for live/dead selections (eBioscience). Samples were then washed and sorted with a MoFlo MLS cell sorter (Beckman Coulter). Effector cells (CD8<sup>+</sup>CD3<sup>+</sup>PI<sup>-</sup> and NK1.1<sup>+</sup>CD3<sup>+</sup>PI<sup>-</sup>) from both brain and blood samples were isolated. Target GL261-fluc cells were cultured in DMEM supplemented with 10% fetal bovine serum. Effector (E) and target (T) cells were added at ratios of 1:1 and 10:1. The plates were spun down at 100 × g for 3 minutes and incubated in 37°C for 4 hours. Luminescence was measured by a Wallac 1420 VICTOR Luminometer (Perkin-Elmer Life and Analytical Sciences, Inc.) and percent cytotoxicity was measured as described previously (18).

Depletion assays

Anti-NK1.1 (clone PK136) was purchased from eBioscience. Hybridoma H35 cells were a kind gift from Dr. Don Diamond (City of Hope, Duarte, CA). Anti-CD8 antibody (clone H35) was produced and purified as previously described (19). Control normal mouse IgG was purchased from Santa Cruz Biotechnology, Inc.

For initial leukocyte depletion studies, mice were treated with anti-CD8, anti-NK1.1, or control IgG (200 μg/mouse, i.p.) 1 day before tumor implantation and each CpG-ODN treatment. Leukocyte depletion was confirmed with fluorescence-activated cell sorting analysis of peripheral blood from treated animals (data not shown).

To check for memory immune response, tumor-bearing mice that had survived multiple CpG-ODN treatments were depleted of CD8 or NK cells (200 μg/mouse, i.p.) 1 day before tumor rechallenge.
Biophotonic tumor imaging

Tumor-bearing animals were injected i.p. with D-luciferin substrate (4.29 mg/mouse; Xenogen). Mice were anesthetized by isoflurane (1.5 L/min oxygen + 4% isoflurane) and kept in an induction chamber. Images were captured with the Xenogen IVIS In Vivo Imaging System (Xenogen). Light emission was measured over an integration time of 1 minute, 12 minutes after injection of luciferin. Luciferase activity was analyzed using Living Image Software (Xenogen) to quantify tumor region flux (photons per second) and to confirm tumor growth.

Statistical analysis

Statistical comparison in all different experimental conditions was done with the Prism software using two-way ANOVA or Student’s t test. Survival was plotted using a Kaplan-Meier survival curve and statistical significance was determined by the log-rank (Mantel-Cox) test. All plots and statistical analysis was done with Prism software. A P value of <0.05 was considered significant.

Results

Multiple low-dose CpG-ODN injections improves survival of glioma-bearing mice

Mice bearing 4-day-old intracranial tumors were treated with one or multiple (two or four) injections of CpG-ODN, control ODN, and PBS every 4 days (Fig. 1). Tumor eradication in CpG-ODN–treated mice was confirmed by biophonic imaging of the GL261-ffLuc tumor (Fig. 1A) and, for a subset of mice, by tumor histology (data not shown). Four intratumoral injections of low-dose CpG-ODN eradicated intracranial gliomas in 71% of mice, whereas multiple injections of control ODN or PBS did not induce a survival benefit (Fig. 1B). The efficacy of CpG-ODN seemed to depend on the number of injections because two CpG-ODN treatments also improved survival (cure rate of 71%), whereas no survival benefit was observed with a single low-dose CpG-ODN injection (Fig. 1C).

Effect of CpG-ODN on cytotoxic CD8 and NK cells

To investigate inflammatory cellular responses to tumor growth and its differences between one versus multiple CpG-ODN injections, mice bearing 4-day-old intracranial tumors were treated with CpG-ODN, control ODN, and PBS once or four times (every 4 days) similar to the survival experiments. Twenty-four hours after the last injection, brain, spleen, and blood were harvested and analyzed by flow cytometry (Fig. 2). Several interesting observations were made in these experiments. First, irrespective of treatment type, the frequency of intratumoral NK cells (45-60%) was much higher than that of CD8 cells (0.5-1%), suggesting a stronger innate immune response to initial tumor implantation. Second, brain, blood, and

![Fig. 2. Effect of CpG-ODN on CD8 and NK cells. Mice bearing 4-d-ol intracranial GL261 tumors were treated with intratumoral CpG-ODN (3 μg/injection), control ODN (3 μg/injection), and PBS once (one inj.) or four (four inj.) times as described in Fig. 1. Twenty-four hours after the last injection, brain, spleen, and blood were harvested and analyzed by flow cytometry for the percentage of CD8 (top) and NK (bottom) cells. P values for significant differences between treatment groups are provided above each bar graph. *, P < 0.05; **, P < 0.001; ***, P < 0.0001, between one and four injections for each treatment. n = 4 mice for each treatment group. Representative data of two separate experiments.](/research/clincancerres/article-figures/3402/fig2.png)
spleen NK cells significantly decreased in frequency as intracranial tumors grew (Fig. 2, bottom, black columns, in one versus four PBS-treated groups, tumors harvested at days 5 and 17, respectively), highlighting the presence of local and systemic immunosuppressive tumor factors. Third, the relative frequency of brain, blood, and spleen NK cells (but not CD8 cells) in the multiple CpG-ODN–treated group was lower than that in the single-injected mice (Fig. 2, bottom, light grey columns, in one versus four CpG-ODN–treated groups) and similar to CpG-ODN–treated normal mice (data not shown). Because most of these animals were tumor-free, this observation suggests that CpG-ODN–induced NK cell response may have directly correlated to the extent of tumor burden. Finally, despite an increase in CD8+ cells, NK cells continue to be more frequent in CpG-ODN–cured animal brains (~2% versus 20%).

**Effect of CpG-ODN on immunosuppressive cells**

Because previous reports have linked CpG-ODN to an increase in immunosuppressive cells (20), we next evaluated the effect of the number of CpG-ODN injections on regulatory T cells (Treg; CD4+CD25+FOXP3+) and myeloid-derived suppressor cells (MDSC; CD11b+Gr-1+). Both Tregs (brain) and MDSCs (brain and blood) increased with tumor growth (Fig. 3, black columns, in one versus four PBS-treated groups), underscoring the role of these cells in tumor immunosuppression. In contrast to Tregs, MDSCs were more prevalent in the blood and significantly increased in the brain, blood, and spleens in response to a single CpG-ODN injection (Fig. 3, one injection CpG-ODN–treated group). These observations suggested that perhaps an influx of MDSCs may have abrogated the stimulatory effects of a single injection of CpG-ODN.

**Intracranial rechallenge of CpG-ODN–treated mice with tumor cells increases NK activity and cytotoxicity**

To determine which cells were mostly responsible for tumor eradication, non–tumor-bearing normal and CpG-ODN–treated mice that had survived for at least 3 months were rechallenged with an intracranial injection of GL261 cells. Three days after rechallenge, brain and blood samples from normal [naïve (N)], GL261-challenged naïve (T), CpG-ODN–treated survived (CS), and GL261-rechallenged CpG-ODN–treated survived mice (CR) were harvested and compared for cytotoxicity activity. Significant increase ($P < 0.001$) in IFNγ production in both brain and blood of the CR group, and

---

**Fig. 3.** Effect of CpG-ODN on Tregs and MDSCs (Gr-1). Mice bearing 4-d-old intracranial GL261 tumors were treated with CpG-ODN (3 μg/injection), control ODN (3 μg/injection), and PBS once (one inj.) or four (four inj.) times as described in Fig. 1. Twenty-four hours after the last injection, brain, spleen, and blood were harvested and analyzed by flow cytometry for Tregs and MDSCs by flow cytometry. $P$ values for significant differences between treatment groups are provided above each bar graph. *, $P < 0.05$; **, $P < 0.001$; ***, $P < 0.0001$, between one and four injections for each treatment. $n = 4$ mice for each treatment group. Representative data of two separate experiments.
to a lesser degree in the T group (\( P < 0.05 \)), confirmed antitumor cytotoxicity activity in response to tumor challenge in both naïve and CpG-ODN–treated mice (Fig. 4A). Although in naïve mice, CD8 activation (CD8+CD107a+) seemed to be more pronounced than NK activation (NK+CD107a+) in the brain, the reverse was seen in the CR group, suggesting that NK cells may be the primary cells responsible for antitumor immunity (Fig. 4B). Furthermore, to compare NK and CD8 anti-glioma cytolytic activities, these cells were isolated from blood and brains of CR mice and incubated with GL261 target cells. Brain NK cell cytotoxicity was significantly higher than that of CD8 cells, suggesting that local activation of NK cells may be responsible for GL261 rejection in the rechallenged CpG-ODN–treated mice (Fig. 4C).

The anti-glioma effect of low-dose CpG-ODN is primarily mediated by NK cells

To verify if the anti-glioma effect of CpG-ODN was solely due to activated NK cells, depleting doses of CD8- or NK-specific antibodies were given 1 day before tumor implantation and before each CpG-ODN treatment. The CpG-ODN antitumor effect was completely abrogated by NK depletion (Fig. 5A and B), whereas depletion of CD8 cells partially reduced tumor growth rate (Fig. 5), confirming that the initial antitumor response by multiple intracranial low-dose CpG-ODN was mostly mediated through NK cell activation.

CpG-ODN–treated mice develop immunity against gliomas

To determine if CpG-ODN treatment induced immunity against gliomas, CpG-ODN–treated GL261-bearing mice that had survived for at least 3 months, along with naïve mice, were rechallenged with an intracranial injection of GL261 glioma or B16-F10 melanoma cells. These “cured” mice developed not only full immunity against GL261 rechallenge (Fig. 6A) but also partial immunity against B16-F10 melanomas (Fig. 6B), suggesting that the antitumor response seen with multiple intracranial CpG-ODN injections was not tumor specific and most likely mediated through NK cell activation. To assess NK anti-glioma cytolytic activity in these mice, NK cells from CpG-ODN–treated rechallenged and GL261–injected naïve mice were incubated with GL261 target cells. The cytotoxicity of NK cells from CpG-ODN–treated rechallenged mice was significantly higher than that of NK cells from GL261–injected naïve mice. These findings strongly suggested that NK cells were reactivated with glioma rechallenge and possibly responsible for the antitumor immunity seen with multiple low-dose CpG-ODN treatments (Fig. 6C).

Fig. 4. Effect of tumor rechallenge on CD8 and NK cell activation. Normal mice and CpG-ODN–treated mice (four injections) that had survived for at least 3 mo after initial tumor inoculation were rechallenged with an intracranial injection of GL261 cells. Brain and blood samples from normal [naïve (N)], GL261–challenged naïve (T), CpG-ODN–treated survived (CS), and GL261–rechallenged CpG-ODN–treated survived mice (CR) were harvested and compared by flow cytometry for IFNγ production (A), activation of CD8 and NK cells (CD107a expression; B), and CD8 and NK cytotoxicity against GL261 target cells (C). ns, not significant; *, \( P < 0.05 \); **, \( P < 0.001 \). n = 4 mice for each treatment group. Representative data of two separate experiments.
Both NK and CD8 cells contribute to the CpG-ODN–induced immunity against gliomas

Finally, to determine if the developed immunity to GL261 gliomas was solely due to reactivation of memory NK cells, CpG-ODN–treated survived mice were depleted of either CD8 or NK cells 1 day before tumor rechallenge. Implanted intracranial GL261-ffluc tumors were rapidly rejected in both groups (Supplementary Fig. S1), indicating either that both NK and CD8 cells played a role in anti-glioma memory or that systemic administration of NK or CD8 antibody was inadequate in depleting anti-tumor memory cells that may have resided in the brain after tumor rejection.

Discussion

TLR9 agonists are potent stimulators of both innate and adaptive immune systems. They induce cytokines, activate NK cells and monocytes, and elicit T-cell responses leading to antitumor effects (21). Based on promising preclinical data, CpG-ODNs are currently being tested as single agents, vaccine adjuvants, or in combination with other therapies in patients with various cancers (22). The efficacy of CpG-ODN immunotherapy has also been studied in brain tumors. Initial reports by Carpentier et al. showed an 88% cure rate in rats bearing intracranial CNS-1 gliomas after multiple direct intratumoral CpG-ODN injections. Interestingly, cured animals were protected from tumor rechallenge 12 weeks after the initial therapy, suggesting induction of antitumor immunity in an organ that is considered “immune-privileged” (23, 24). Since then, however, a number of investigators have reported variable CpG-ODN anti-glioma responses ranging from no efficacy (25), to partial response (9), to complete tumor eradication (26). Although differences in CpG-ODN constructs and glioma models could account for these inconsistent antitumor responses, most glioma studies have evaluated high doses of CpG-ODN (10-100 μg/mice or 100-200 μg/rat). Furthermore, the proinflammatory response of high intracranial CpG-ODN therapy could limit the clinical efficacy of this agent because brain edema, which is frequently present in patients with malignant brain tumors, may directly influence its dose-limiting toxicity. In fact, in clinical trials using convection-enhanced intratumoral CpG-28 delivery conducted in patients with recurrent malignant glioma, a number of patients treated at the highest dose (20 mg) experienced neurologic worsening or seizures most likely related to the proinflammatory effects of CpG-28 (7, 12). One way to overcome this limitation is to use CpG-ODN in combination with radiation or as a vaccine adjuvant (25, 27). Here, however, we report that multiple low-dose intratumoral injections of CpG-ODN can be as effective in eradicating established intracranial gliomas, without causing significant brain edema or inflammation. This approach was well tolerated by animals, and suggests that clinically improved efficacy with decreased therapy-related side effects can be achieved by repetitive injections of low-dose CpG-ODN.

Fig. 5. The anti-glioma effect of low-dose CpG-ODN is primarily mediated by NK cells. Naïve mice were depleted of CD8 or NK cells by i.p. injection of relevant monoclonal antibody or control IgG (200 μg/injection) 1 d before tumor implantation and each CpG-ODN treatment (3 μg/injection; arrows). A, intracranial tumor burden was assessed by biophotonic imaging of mice at days 14 and 21 after tumor implantation. NK-depleted mice exhibited more rapid tumor growth. B, Kaplan-Meier analysis shows lower survival rate for mice that were depleted of NK cells (P = 0.348), n = 6 mice for each group. Representative data of two separate experiments.
The exact antitumor mechanism of CpG-ODN is not clear but is most likely due to both tumor cell apoptosis and immune activation. TLR9 is not only expressed on inflammatory cells but is also present on gliomas (9, 28). CpG-ODN is efficiently taken up by glioma cells and induces apoptosis in vitro (9, 29). In vivo, direct intracranial CpG-ODN injection induces an inflammatory response mediated through activated T cells, NK cells, and glioma-infiltrating macrophages and microglia (30, 31). Using depletion studies, Roda et al. showed that both NK and T cells contributed to tumor elimination (32). Our study confirmed that low-dose CpG-ODN also stimulated both CD8 and NK cells, but NK cells seemed to play a more significant role in the initial antitumor response. NK cell depletion completely abrogated the therapeutic effect of low-dose CpG-ODN, whereas CD8 depletion only retarded tumor growth. Furthermore, when CpG-ODN–cured mice were rechallenged with intracranial tumors, a strong local NK cell response was noted in the brain. Because NK levels returned to baseline in CpG-ODN–cured mice, this finding suggests that perhaps activation of memory NK cells may have been responsible for antitumor immunity.

NK cells are important components of the innate immune system because they are cytotoxic toward tumor cells or virally infected cells without prior exposure to antigens and rapidly secrete IFNγ and other cytokines that activate the innate as well as adaptive immune responses (33). Although traditionally NK cells have been classified as cells of the innate immune system, in recent years the presence of immunologic “memory” NK cells has been reported (34, 35). Recent reports by Sun et al. have shown that NK cells show similar memory type characteristics as CTLs (35). In our study, the initial CpG-ODN injection caused an increase in NK population, which subsided after the fourth treatment and correlated with tumor rejection. Also, CpG-ODN–treated “cured” mice had low systemic levels of NK cells, similar to naïve mice. However, with tumor rechallenge, a robust NK cell response was noted in the brain and these mice were protected not only from glioma but also from an unrelated tumor type. Interestingly, even after CD8 depletion, CpG-ODN–treated cured mice remained protected against intracranial tumor rechallenge. This antitumor NK cell response mimics the expansion, contraction, memory maintenance, and recall characteristic of memory NK cell responses (35).

Intratumoral NK infiltration was seen within the first week of tumor implantation, but these cells significantly decreased in frequency as tumors continued to grow. NK

![Fig. 6.](image-url)
cell population retracted not only in the tumors but also in the blood and spleen of glioma-bearing mice, most likely as a result of immunosuppressive factors secreted by gliomas (6). In addition to inhibitory cytokines, some inflammatory cell types within gliomas can play a role in immune tolerance. Of note, Tregs can actively suppress T and NK cell immune responses (36–38). Consistent with other reports, we detected a significant expansion of tumor Tregs in tumor-bearing mice that decreased in response to CpG-ODN therapy. A significant increase in the CD4 and CD8 to Treg ratio was also reported to be important in induction of anti-glioma response to high-dose CpG-ODN by Grauer et al. (26). In our studies, however, Tregs accounted for only a small fraction of inflammatory cells and were not as prevalent as MDSCs, which can also play a role in tumor immune escape.

MDSCs are a heterogeneous population of cells of myeloid origin that have been reported to suppress the immune system and promote tumor growth (39). Studies have linked MDSCs to suppression of T cells (40–44), NK T cells (45), and NK cells (46, 47). Makarenkova et al. showed that MDSC expression of l-arginine (arginase-mediated) may be the cause of T-cell dysfunction following surgery and trauma (48). Recently, other studies have linked MDSCs to the suppression of NK cytotoxicity (46, 47). In one report, isolated CD11b+Gr-1+ cells from tumor-bearing mice abrogated the NK cell ability to kill target cells (47). Also, Li et al. (46) recently showed that in tumor-bearing mice, MDSCs can suppress NK cytotoxicity by inhibiting NKG2D expression and IFNγ production. Consistent with other reports, our study showed that single CpG-ODN injection resulted in a significant increase in CD11b+Gr-1+ cells (20, 49). Because multiple CpG-ODN injections were not associated with a significant Gr-1+ flux in spleen or blood, we postulate that the induction of MDSCs after the first CpG-ODN injection may have suppressed the initial anti-glioma NK response. This hypothesis will be tested in future studies.

In summary, we showed that multiple low-dose intratumoral injections of CpG-ODN can eradicate intracranial gliomas and induce immunity against tumor rechallenge. The activation of NK cells following CpG-ODN treatment or rechallenge of CpG-ODN cured mice and the partial immunity against B16-F10 melanomas strongly suggested the involvement of a NK response. Furthermore, suppression of MDSC response following multiple CpG-ODN injections may have played a role in NK cell activation and induction of memory response. Future experiments will assess the role of MDSC depletion in CpG-ODN immunotherapy of gliomas.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

NIH grant R21CA131765-01A2 and the James S. McDonnell Foundation (B. Badie). The City of Hope Flow Cytometry Core was equipped in part through funding provided by ONR N00014-02-1 0958, DOD 1435-04-03GT-73134, and NSF DBI-9970143.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 11/24/2009; revised 04/21/2010; accepted 04/27/2010; published OnlineFirst 06/22/2010.

References


Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy

Darya Alizadeh, Leying Zhang, Christine E. Brown, et al.

Clin Cancer Res  Published OnlineFirst June 22, 2010.

Updated version  Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-09-3087

Supplementary Material  Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2010/08/25/1078-0432.CCR-09-3087.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.